Pharming Group (NASDAQ:PHAR) Price Target Raised to $39.00 at Oppenheimer

Pharming Group (NASDAQ:PHAR) had its target price boosted by research analysts at Oppenheimer from $30.00 to $39.00 in a note issued to investors on Friday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Oppenheimer’s target price indicates a potential upside of 343.94% from the company’s current price.

Several other equities analysts also recently weighed in on PHAR. HC Wainwright restated a “buy” rating and issued a $37.00 price objective on shares of Pharming Group in a research report on Friday. Jefferies Financial Group began coverage on shares of Pharming Group in a research note on Monday, December 9th. They set a “buy” rating and a $14.00 price target on the stock.

Pharming Group Stock Performance

Pharming Group stock traded up $0.05 during midday trading on Friday, hitting $8.79. 1,156 shares of the company’s stock were exchanged, compared to its average volume of 6,175. The firm’s 50 day simple moving average is $9.05 and its 200 day simple moving average is $8.57. The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.76 and a current ratio of 3.53. The stock has a market cap of $597.65 million, a price-to-earnings ratio of -33.78 and a beta of -0.10. Pharming Group has a 12-month low of $6.65 and a 12-month high of $11.80.

Pharming Group (NASDAQ:PHAR) last announced its quarterly earnings data on Thursday, March 13th. The company reported $0.05 EPS for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.02). Pharming Group had a negative net margin of 6.09% and a negative return on equity of 7.65%. Equities research analysts predict that Pharming Group will post -0.2 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC lifted its position in shares of Pharming Group (NASDAQ:PHAR) by 16.8% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 47,997 shares of the company’s stock after acquiring an additional 6,887 shares during the period. Silverberg Bernstein Capital Management LLC owned 0.07% of Pharming Group worth $483,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 0.03% of the company’s stock.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.